• 1
    Spira A, Ettinger DS. Multidisciplinary management of lung cancer. N Engl J Med. 2004; 22: 350: 379-392.
  • 2
    Pignon J-P, Arriagada R, Ihde DC, et al. A meta-analysis of thoracic radiotherapy for small-cell lung cancer. N Engl J Med. 1992; 327: 1618-1624.
  • 3
    NCCN Physician Guidelines Index. Available at: Accessed May 13, 2008.
  • 4
    Armstrong J, McGibney C. The impact of 3-dimensional radiation on the treatment of non-small cell lung cancer. Radiother Oncol. 2000; 56: 157-167.
  • 5
    Emami B, Graham MV, Purdy JA. Three-dimensional conformal radiotherapy in bronchogenic carcinoma: considerations for implementation. Lung Cancer. 1994; 11( suppl 3): S117-S128.
  • 6
    Perez CA, Purdy JA, Harms W, et al. Three-dimensional treatment planning and conformal radiation therapy: preliminary evaluation. Radiother Oncol. 1995; 36: 32-43.
  • 7
    Grills IS, Yan D, Martinez AA, et al. Potential for reduced toxicity and dose escalation in the treatment of inoperable non-small-cell lung cancer: a comparison of intensity-modulated radiation therapy (IMRT), 3D conformal radiation, and elective nodal irradiation. Int J Radiat Oncol Biol Phys. 2003; 57: 875-890.
  • 8
    Sura S, Gupta V, Yorke E, et al. Intensity-modulated radiation therapy (IMRT) for inoperable non-small cell lung cancer: the Memorial Sloan-Kettering Cancer Center (MSKCC) experience. Radiother Oncol. 2008; 87: 17-23.
  • 9
    Onishi H, Araki T, Shirato H, et al. Stereotactic hypofractionated high-dose irradiation for stage I non-small cell lung carcinoma: clinical outcomes in 245 subjects in a Japanese multi-institutional study. Cancer. 2004; 101: 1623-1631.
  • 10
    Widesott L, Amichetti M, Schwarz M. Proton therapy in lung cancer: clinical outcomes and technical issues. A systematic review. Radiother Oncol. 2008; 86: 154-164.
  • 11
    Potosky AL, Riley GF, Lubitz JD, et al. Potential for cancer related health services research using a linked Medicare-tumor registry database. Med Care. 1993; 31: 732-748.
  • 12
    Percy C, Van Holten V, Muir C. International Classification of Diseases for Oncology. 2nd ed. Geneva, Switzerland: World Health Organization; 1990.
  • 13
    Sundararajan V, Mitra N, Jacobson JS, et al. Survival associated with 5-fluorouracil-based adjuvant chemotherapy among elderly patients with node-positive colon cancer. Ann Intern Med. 2002; 136: 349-357.
  • 14
    Ramsey SD, Howlader N, Etzioni RD, et al. Chemotherapy use, outcomes, and costs for older persons with advanced non-small-cell lung cancer: evidence from surveillance, epidemiology and end results-Medicare. J Clin Oncol. 2004; 22: 4971-4978.
  • 15
    Bach PB, Cramer LD, Warren JL, et al. Racial differences in the treatment of early-stage lung cancer. N Engl J Med. 1999; 341: 1198-1205.
  • 16
    Earle CC, Tsai JS, Gelber RD, et al. Effectiveness of chemotherapy for advanced lung cancer in the elderly: instrumental variable and propensity analysis. J Clin Oncol. 2001; 19: 1064-1070.
  • 17
    Virnig BA, Warren JL, Cooper GS, et al. Studying radiation therapy using SEER-Medicare-linked data. Med Care. 2002; 40( 8 suppl): IV-49-IV-54.
  • 18
    Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol. 1992; 45: 613-619.
  • 19
    Klabunde CN, Potosky AL, Legler JM, et al. Development of a comorbidity index using physician claims data. J Clin Epidemiol. 2000; 53: 1258-1267.
  • 20
    Cooper GS, Virnig B, Klabunde CN, et al. Use of SEER-Medicare data for measuring cancer surgery. Med Care. 2002; 40: IV-43-IV-48.
  • 21
    Warren JL, Harlan LC, Fahey A, et al. Utility of the SEER-Medicare data to identify chemotherapy use. Med Care. 2002; 40: IV-55-IV-61.
  • 22
    Kaplan EL, Maier P. Nonparametric estimation for incomplete observations. J Am Stat Assoc. 1958; 53: 457-481.
  • 23
    Cox DR. Regression models and life tables. J R Soc Ser B. 1972; 34: 187-202.
  • 24
    Rosner B. Fundamentals in Biostatistics. Belmont, CA: Wadsworth Publishing; 1995.
  • 25
    Mountain CF. Revisions in the International System for Staging Lung Cancer. Chest. 1997; 111: 1710-1717.
  • 26
    Dillman RO, Seagren SL, Propert KJ, et al. A randomized trial of induction chemotherapy plus high-dose radiation versus radiation alone in stage III non-small-cell lung cancer. N Engl J Med. 1990; 323: 940-945.
  • 27
    Sause W, Kolesar P, Taylor SIV, et al. Final results of phase III trial in regionally advanced unresectable non-small cell lung cancer: Radiation Therapy Oncology Group, Eastern Cooperative Oncology Group, and Southwest Oncology Group. Chest. 2000; 117: 358-364.
  • 28
    Fournel P, Robinet G, Thomas P, et al. Randomized phase III trial of sequential chemoradiotherapy compared with concurrent chemoradiotherapy in locally advanced non-small-cell lung cancer: Groupe Lyon-Saint-Etienne d'Oncologie Thoracique-Groupe Franc¸ais de Pneumo-Cancerologie NPC 95-01 Study. J Clin Oncol. 2005; 23: 5910-5917.
  • 29
    Schiller JH, Harrington D, Belani CP, et al. Comparison of 4 chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med. 2002; 346: 92-98.
  • 30
    Graham MV, Purdy JA, Emami B, et al. Clinical dose-volume histogram analysis for pneumonitis after 3D treatment for non-small cell lung cancer (NSCLC). Int J Radiat Oncol Biol Phys. 1999; 45: 323-329.
  • 31
    Finkelstein DM, Ettinger DS, Rucksdeschel JC. Long-term survivors in metastatic non-small-cell lung cancer: an Eastern Cooperative Group Study. J Clin Oncol. 1986; 4: 702-709.
  • 32
    Ries LA. Influence of extent of disease, histology, and demographic factors on lung cancer survival in the SEER population-based data. Semin Surg Oncol. 1994; 10: 21-30.
  • 33
    Hutchins LF, Unger JM, Crowley JJ, Coltman JA, Albain KS. Underrepresentation of patients 65 years of age or older in cancer-treatment trials. N Engl J Med. 1999; 341: 2061-2067.
  • 34
    Lewis JH, Kilgore ML, Goldman DP, et al. Participation of patients 65 years of age or older in cancer clinical trials. J Clin Oncol. 2003; 21: 1383-1389.